Mounjaro (Tirzepatide) and Pancreatitis: When to Call the Doctor

What does the Mounjaro label say to watch for?

Section 5.2 of the Mounjaro prescribing information (label effective 2026-08-27) states that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or with Mounjaro [1]. It tells prescribers to observe patients carefully after starting the drug for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by nausea or vomiting [1]. If pancreatitis is suspected, the label says to discontinue Mounjaro and initiate appropriate management [1].

How do I tell pancreatitis pain from ordinary stomach upset?

Nausea, vomiting and diarrhea are common with Mounjaro. In the Mounjaro label's pooled placebo-controlled trials in adults with type 2 diabetes (235 on placebo, 237 on 5 mg, 240 on 10 mg, 241 on 15 mg; mean exposure 36.6 weeks), nausea occurred in 12%, 15% and 18% of the 5, 10 and 15 mg groups versus 4% on placebo; diarrhea in 12%, 13% and 17% versus 9%; and vomiting in 5%, 5% and 9% versus 2% [1]. Most reports of nausea, vomiting and diarrhea came during dose escalation and decreased over time [1]. Severe gastrointestinal adverse reactions were reported by 1.3%, 0.4% and 1.2% of the 5, 10 and 15 mg groups versus 0.9% on placebo [1].

How often does tirzepatide actually cause pancreatitis?

A 2023 systematic review and meta-analysis pooled nine randomized trials with 9,871 participants (6,828 on tirzepatide, 3,043 controls) and compared tirzepatide with placebo, basal insulin, dulaglutide and semaglutide [2]. Pancreatitis was not significantly increased: risk ratio 1.46, 95% CI 0.59 to 3.61 [2]. The confidence interval is wide, so the estimate does not rule out an increased risk [2].

A 2025 meta-analysis of 21 trials and 99,599 patients treated with GLP-1 receptor agonists, including tirzepatide, found no difference in pancreatitis between treated patients and controls [4]. A 2025 review of real-world data on liraglutide, semaglutide and tirzepatide likewise reported no clear increase in severe events such as pancreatitis [5].

Type 2 diabetes and pancreatitis risk

In a retrospective cohort using US health care claims, 337,067 adults with type 2 diabetes were matched by age and sex to 337,067 adults without diabetes, and the diabetes group had 2.83 times the risk of pancreatitis (95% CI 2.61 to 3.06) [3]. The excess was largest in younger patients: incidence rate ratio 5.26 (95% CI 4.31 to 6.42) under age 45 versus 2.44 at age 45 and older [3].

Gallbladder pain is a separate label warning

Acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of Mounjaro-treated adults and 0% of placebo-treated adults in the label's placebo-controlled trials [1]. The 2023 meta-analysis found a significantly higher risk of the composite gallbladder or biliary disease outcome with tirzepatide versus placebo or basal insulin (RR 1.97, 95% CI 1.14 to 3.42) [2], and the 2025 GLP-1 receptor agonist meta-analysis found a 26% increase in gallbladder disorders across the class [4]. Biliary disease is a major cause of pancreatitis [3].

What to have ready when you call

The date and time of your last Mounjaro dose, where the pain sits and how severe it is, whether it moves toward the back, whether eating changes it, and any nausea, vomiting or fever. Also have your other medicines to hand, including insulin or a sulfonylurea, since the label notes that combining Mounjaro with either raises the risk of hypoglycemia [1].